Top Markets
Coin of the day
Sangui Biotech International, Inc. Sangui Biotech International, Inc.

Sangui Biotech International, Inc.

SGBI
Peringkat dalam Saham #41118
Sangui Biotech International, Inc., through its subsidiary Sangui BioTech GmbH,... Sangui Biotech International, Inc., through its subsidiary Sangui BioTech GmbH, specializes in creating artificial oxygen carriers derived from hemoglobin. These innovative products are utilized as blood supplements, blood volume replacements, and various related formulations. The company's oxygen carriers are vital for delivering oxygen to humans experiencing acute or chronic oxygen deprivation due to conditions like blocked arteries, anemia, or blood loss, as well as for managing chronic wounds. Their product line also includes nano-formulations designed for skin regeneration, enhancing moisture and elasticity. Furthermore, they provide Chitoskin wound pads to aid in healing and Hemospray, a medical-grade spray specifically formulated for treating persistent wounds. The wound spray products, marketed under the Granulox brand, are primarily distributed in Europe and Mexico, while their cosmetic items are available through an online store. Established in 1995, Sangui Biotech International, Inc. is based in Hamburg, Germany.
Harga Saham
$0.0002
Terakhir disinkronkan: 2025-07-02
Kapitalisasi Pasar
$41.98K
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
DE
Perdagangan Sangui Biotech International, Inc. (SGBI)

Kategori

Laba untuk Sangui Biotech International, Inc. (SGBI)
Laba pada 2026 TTM: 0
Menurut laporan keuangan terbaru dari Sangui Biotech International, Inc., laba saat ini perusahaan adalah 0. Pada tahun 2026, perusahaan memperoleh laba sebesar 0, sama dengan laba tahun 2026 sebesar 0. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Sangui Biotech International, Inc. dari 2026 hingga 2026
Laba pada akhir setiap tahun
Tahun Laba Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Laba untuk perusahaan serupa atau pesaing